摘要
目的探讨尿激酶联合选择性埋管引流治疗包裹性胸腔积液最佳给药时机。方法将80例包裹性胸腔积液患者按随机数字表法分为A组和B组,每组40例。A组采取分次引流后同时注入尿激酶,每次引流后即从引流管注入尿激酶20万U,同时封管24 h再开放引流,如此反复操作直至无胸液流出。B组患者在埋管引流后至无胸液流出,再在胸腔内注入尿激酶20万U封管,24 h再开放引流,直至无胸液流出。2周后评估2组治疗效果。结果 A组患者引流量、包裹消失时间、住院时间均较B组明显减少,2组比较差异具有统计学意义(P<0.05)。A组胸膜增厚患者明显少于B组,2组比较差异具有统计学意义(P<0.05)。A组总有效率为97.5%,B组为80.0%,2组比较差异具有统计学意义(P<0.05)。2组均无明显的不良反应发生。结论治疗包裹性胸腔积液埋管分次引流后同时注入尿激酶,该方法效果明确,值得应用。
Objective To investigate the best timing of combined treatment with urokinase and selective pipe drainage for encapsulated pleural effusion. Methods Eighty patients with encapsulated pleural effusion were randomly divided into two groups, with 40 patients in each group. In group A, urokinase （200 000 U）was injected through the drainage tube after each drainage and open drainage was performed after tube sealing for 24 hours. The procedure was repeated until pleural fluid disappeared. In group B, urokinase （200 000 U）was intrapleurally administered after pipe drainage and open drainage was performed after tube sealing for 24 hours until pleural fluid disappeared. Curative effects were evaluated after 2 weeks. Results Compared with group B, the drainage volume, encapsu- lation extinction time, hospital stay and incidence of pleural thickening significantly decreased in group A （P〈0.05）. Furthermore, the total effective rate in group A was obviously higher than that in group B （97.5% vs 80.0% ,P〈0.05）. No significant side effects were found in both groups. Conclusion Urokinase injection after fractionation drainage is effective and should be used in patients with encapsulated pleural effusion.
出处
《实用临床医学（江西）》
CAS
2013年第3期10-12,共3页
Practical Clinical Medicine
关键词
尿激酶
包裹性胸腔积液
引流
给药时间
urokinase
encapsulated pleural effusion
drainage
administration time
